The National Institute for Health and Care Excellence (Nice) is concerned about the number of people regaining weight after ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

FAT jabs are not a “quick fix” and patients must be followed up for at least a year to keep the weight off, the NHS watchdog ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

When it comes to weight loss, there are a number of tried and true lifestyle changes you can make to help you along the way.

People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.

Patients coming off Wegovy or Mounjaro should have support and advice for at least a year afterwards, NHS told.

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Experts say NHS patients should be monitored for at least a year after treatment ends, with tailored support provided if ...